Susceptibility to novel antimicrobial agents and molecular epidemiology of carbapenem-resistant enterobacterales: a 9-year study in Central China - PubMed
4 hours ago
- #CRE Epidemiology
- #Novel Antibiotics
- #Antimicrobial Resistance
- 9-year surveillance study of carbapenem-resistant Enterobacterales (CRE) in Central China, with CRKP (65.5%) as the dominant type.
- Among 133 representative CRE strains, 97.7% carried carbapenemase genes, primarily blaKPC-2 (82.7%), with the high-risk CRKP-ST11-blaKPC-2 clone being predominant.
- Cefiderocol and aztreonam-avibactam showed 100% susceptibility against all tested CRE strains.
- Against blaKPC-2 producers, ceftazidime-avibactam, imipenem-relebactam, and meropenem-vaborbactam had susceptibility rates of 92.7%, 96.4%, and 97.3%, respectively.
- Some NDM-producing (44.4%) and one IMP-4-producing isolates were susceptible to meropenem-vaborbactam, linked to low-level carbapenem resistance and absence of co-produced serine β-lactamases.
- Temporal variation in CRE proportion observed, with a decline from 2020-2022 and an increase after 2023.
- Study concludes with a need for sustained infection control and further clinical studies to confirm real-world efficacy of novel antimicrobial agents.